Clinical trials: RhA - Rheumatoid Arthritis
Rheumatoid Arthritis
A Study Of Tocilizumab in Patients With Moderate to Severe Active Rheumatoid Arthritis Who Have an Inadequate Response to or Are Unable to Tolerate Biologic and Non-Biologic Disease-modifying Antirheumatic Drugs (DMARDs)
This 3 arm randomized open label study will evaluate the safety, tolerability and efficacy of tocilizumab in patients with moderate to severe active rheumatoid arthritis, who have had inadequate response to or are unable to…
- Trial name
- NCT00891020
- Testing
- tocilizumab [RoActemra/Actemra], Nonbiologic DMARDs of investigator's choice
- Where
- 227 sites in United States
- Volunteers
- 886 people
- Sponsor
- Hoffmann-La Roche
Rheumatoid Arthritis
A Comparative Study Between PF-06410293 and Humira® in Combination With Methotrexate in Participants With Active Rheumatoid Arthritis
The study will assess the impact of pharmacokinetics (PK), safety and immunogenicity after switches between PF-06410293 and adalimumab and with continuous dosing with adalimumab in combination with methotrexate in subjects with…
- Trial name
- NCT04230213
- Testing
- PF-06410293, adalimumab
- Where
- 72 sites in United States, Bosnia and Herzegovina and 8 more
- Volunteers
- 455 people
- Sponsor
- Pfizer
Arthritis, Rheumatoid
Safety and Efficacy of BI 695500 in Patients With Moderately to Severely Active Rheumatoid Arthritis
The primary objective of this trial is to evaluate the long-term safety of BI 695500 in adult patients with moderately to severely active rheumatoid arthritis (RA) who have successfully completed treatment in Trial 1301.1.
- Trial name
- NCT01955733
- Testing
- BI 695500
- Where
- 43 sites in United States, Belgium and 7 more
- Volunteers
- 91 people
- Sponsor
- Boehringer Ingelheim
Rheumatoid Arthritis
A Long-Term Extension Study of WA22762 to Evaluate Safety and Efficacy of Subcutaneous Tocilizumab in Participants With Moderate to Severe Rheumatoid Arthritis (RA).
This multicenter, open-label, single arm, interventional, long-term extension (LTE) study will evaluate the safety and efficacy of tocilizumab (TCZ, RoActemra/Actemra) in French participants with moderate to severe RA who have…
- Trial name
- NCT01734993
- Testing
- Tocilizumab
- Where
- 6 sites in France
- Volunteers
- 11 people
- Sponsor
- Hoffmann-La Roche
Arthritis, Rheumatoid
A Study to Evaluate the Nipocalimab and Certolizumab Combination Therapy in Participants With Active Rheumatoid Arthritis
The purpose of this study is to evaluate the efficacy of combination therapy with nipocalimab and certolizumab compared to certolizumab monotherapy.
- Trial name
- DAISY (NCT06028438)
- Testing
- Nipocalimab, Certolizumab
- Where
- 32 sites in United States, Argentina and 4 more
- Volunteers
- 103 people
- Sponsor
- Janssen Research & Development, LLC
Arthritis, Rheumatoid
A Study Comparing 2 Doses Of CP-690,550 Vs. Placebo For The Treatment Of Rheumatoid Arthritis In Patients On Other Background Arthritis Medications
This Phase 3 study is intended to provide evidence that CP-690,550 dosed 5 mg BID and 10 mg BID is safe and effective when used in combination with a variety of traditional disease modifying antirheumatic drugs in adult patients…
- Trial name
- NCT00856544
- Testing
- CP-690,550
- Where
- 133 sites in United States, Australia and 18 more
- Volunteers
- 795 people
- Sponsor
- Pfizer
Rheumatoid Arthritis
A Study of Tocilizumab (RoActemra) in Tocilizumab-Naive Participants With Rheumatoid Arthritis and Inadequate Response to Non-Biologic Disease-Modifying Antirheumatic Drugs (DMARDs) and/or Biologic Therapy
This two part, multi-center, open-label, single-arm study will evaluate the efficacy and safety of tocilizumab as a monotherapy or in combination with methotrexate or other conventional synthetic disease modifying antirheumatic…
- Trial name
- TOSCA (NCT02001987)
- Testing
- Tocilizumab, Methotrexate, csDMARDs
- Where
- 32 sites in France
- Volunteers
- 139 people
- Sponsor
- Hoffmann-La Roche
Osteoarthritis, Rheumatoid Arthritis
Efficacy and Safety of Buprenorphine Transdermal Patch in Non-cancer Pain of Moderate Intensity
This is a phase IV, open-label and single-arm study of patients with non-malignant pain due to osteoarthritis, rheumatoid arthritis, low back pain and joint/muscle pain, who were not responding to non-opioid analgesics.
- Conditions
- Osteoarthritis, Rheumatoid Arthritis, Lower Back Pain, Joint Pain
- Trial name
- NCT02519387
- Testing
- Buprenorphine Transdermal Patch
- Where
- 3 sites in Malaysia
- Volunteers
- 78 people
- Sponsor
- Mundipharma Pharmaceuticals Sdn. Bhd.
Autoimmune Disorder, Rheumatoid Arthritis
Study to Assess Safety and Effectiveness of Branebrutinib Treatment in Participants With Active Systemic Lupus Erythematosus or Primary Sjögren's Syndrome, or Branebrutinib Treatment Followed by Open-label Abatacept Treatment in Study Participants With Active Rheumatoid Arthritis
The purpose of this study is to evaluate the safety and effectiveness of treatment with branebrutinib treatment in participants with active systemic Lupus Erythematosus (SLE) or Primary Sjögren's Syndrome (pSS), or branebrutinib…
- Conditions
- Autoimmune Disorder, Rheumatoid Arthritis, Systemic Lupus Erythematosus, Primary Sjögren's Syndrome
- Trial name
- NCT04186871
- Testing
- branebrutinib, abatacept
- Where
- 81 sites in United States, Argentina and 8 more
- Volunteers
- 119 people
- Sponsor
- Bristol-Myers Squibb
Rheumatoid Arthritis
Evaluation of the Efficacy and Safety of Two Dosing Regimens of Olokizumab (OKZ), Compared to Placebo and Adalimumab, in Subjects With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate But Have Active Disease
The purpose of this study was to determine how effective and safe the study drug Olokizumab was in patients with Rheumatoid Arthritis (RA) who had been already receiving but not fully responding to treatment with methotrexate…
- Trial name
- CREDO 2 (NCT02760407)
- Testing
- Olokizumab 64mg q4w, Olokizumab 64mg q2w, Adalimumab 40mg q2w
- Where
- 203 sites in United States, Argentina and 16 more
- Volunteers
- 1,648 people
- Sponsor
- R-Pharm International, LLC
Rheumatoid Arthritis
A Study of the Efficacy and Safety of Tocilizumab in Adults With Rheumatoid Arthritis.
A multi-center, open-label single-arm study to evaluate the efficacy and safety of tocilizumab administered as a single, weekly injection in adults with rheumatoid arthritis.
- Trial name
- NCT01988012
- Testing
- tocilizumab
- Where
- 13 sites in Israel
- Volunteers
- 100 people
- Sponsor
- Hoffmann-La Roche
Arthritis, Rheumatoid
Study to Assess if ABP 798 is Safe & Effective in Treating Moderate to Severe Rheumatoid Arthritis (RA) Compared to Rituximab
This trial is designed to determine what effects the human body has on the investigational medicine, ABP 798, and what effects the body has on the investigational medicine after you have been given it, and if this is comparable…
- Trial name
- NCT02792699
- Testing
- ABP 798, Rituximab (US), Rituximab (EU)
- Where
- 55 sites in United States, Bulgaria and 4 more
- Volunteers
- 311 people
- Sponsor
- Amgen
Rheumatoid Arthritis
A Study to Evaluate the Effectiveness and Safety of SKI-O-703 in Patients Experiencing Active Rheumatoid Arthritis Despite Treatment With Conventional Therapies.
This study will evaluate the safety and efficacy of SKI-O-703 compared with placebo, in patients with active rheumatoid arthritis (RA) who have had an inadequate response to conventional synthetic disease-modifying agents.
- Trial name
- NCT04057118
- Testing
- SKI-O-703
- Where
- 40 sites in United States, Czechia and 3 more
- Volunteers
- 163 people
- Sponsor
- Oscotec Inc.
Rheumatoid Arthritis
Substudy - Low Dose of Abatacept in Subjects With Rheumatoid Arthritis
The purpose of this exploratory sub-study was to evaluate from a clinical perspective the impact on disease activity of lowering the dose of abatacept from 10 mg/kg to 5 mg/kg in subjects who had achieved remission (Disease…
- Trial name
- NCT00989235
- Testing
- Abatacept
- Volunteers
- 108 people
- Sponsor
- Bristol-Myers Squibb
Rheumatoid Arthritis
Evaluation of Safety and Effectiveness of Fostamatinib Compared to Placebo in Patients in Asia With Rheumatoid Arthritis
The purpose of the study is to evaluate the effectiveness of four dosing regimens of fostamatinib compared to placebo, in patients with rheumatoid arthritis (RA) who are taking methotrexate but not responding.
- Trial name
- OSKIRA-Asia-1 (NCT01569074)
- Testing
- Fostamatinib
- Where
- 34 sites in Hong Kong, Japan and 4 more
- Volunteers
- 163 people
- Sponsor
- AstraZeneca
Rheumatoid Arthritis, Psoriasis
A Study of Experimental Medication BMS-986251, Taken by Mouth, in Healthy Participants and Patients With Average to Very Serious Psoriasis
The purpose of this study is to investigate experimental medication BMS-986251 taken by mouth in healthy patients and patients with average to very serious Psoriasis (a condition characterized by itchy, dry skin with a scaly…
- Conditions
- Rheumatoid Arthritis, Psoriasis, Ankylosing Spondylitis, Inflammatory Bowel Diseases
- Trial name
- NCT03329885
- Testing
- BMS-986251
- Where
- Netherlands
- Volunteers
- 38 people, healthy volunteers welcome
- Sponsor
- Bristol-Myers Squibb
Rheumatoid Arthritis
A Study of Baricitinib in Participants With Rheumatoid Arthritis
This post-marketing study is designed to compare the safety of baricitinib versus tumor necrosis factor (TNF) inhibitors with respect to venous thromboembolic events (VTEs) when given to participants with rheumatoid arthritis…
- Trial name
- RA-BRANCH (NCT04086745)
- Testing
- Baricitinib, TNF Inhibitor
- Where
- 119 sites in United States
- Volunteers
- 1,050 people
- Sponsor
- Eli Lilly and Company
Rheumatoid Arthritis, Ankylosing Spondylitis
Post-marketing Observational Study to Evaluate the Incremental Impact of AbbVie's Patient Support Program on Patient Reported Outcomes and Health Resource Utilization in Inflammatory Arthritis, Psoriasis and Inflammatory Bowel Diseases in Hungary (VALUE)
The objective of this post-marketing observational study (PMOS) was to evaluate the effectiveness of adalimumab plus the AbbVie Care 2.0 patient support program in participants with rheumatoid arthritis (RA), ankylosing…
- Conditions
- Rheumatoid Arthritis, Ankylosing Spondylitis, Psoriatic Arthritis, Psoriasis
- Trial name
- VALUE (NCT02750800)
- Testing
- Adalimumab, AbbVie Care 2.0
- Volunteers
- 427 people
- Sponsor
- AbbVie
Rheumatoid Arthritis
Induction of Remission in RA Patients at Low Disease Activity by Additional Infliximab Therapy (Study P04644AM1) (TERMINATED)
This Phase 3, randomized, open-label, multicenter study in rheumatoid arthritis (RA) patients with low disease activity (Disease Activity Score 28 [DAS28] >2.8 and <3.5) is being conducted to evaluate induction of remission by…
- Trial name
- NCT00521924
- Testing
- infliximab, DMARDs (methotrexate; chloroquine; leflunomidum; cyclosporin A; sulfasalazine; OM 89.
- Volunteers
- 8 people
- Sponsor
- Merck Sharp & Dohme LLC
Gastric Ulcer, Duodenal Ulcer
Long Term Study to Investigate the Efficacy & Safety of D961H (Esomeprazole) for the Prevention of NSAIDs-induced Ulcer
The purpose of this study is to assess the Safety and tolerability of D961H (Esomeprazole) 20 mg once daily for up to 52 weeks of treatment involving patients with a history of gastric and/or duodenal ulcers receiving daily…
- Conditions
- Gastric Ulcer, Duodenal Ulcer, Rheumatoid Arthritis, Osteoarthritis
- Trial name
- NCT00595517
- Testing
- Esomeprazole 20 mg
- Where
- 3 sites in Japan
- Volunteers
- 395 people
- Sponsor
- AstraZeneca